Company Description
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally.
Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers.
It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms.
OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions.
The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
| Country | United States |
| IPO Date | May 5, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 85 |
| CEO | David Elliot Lazar |
Contact Details
Address: 9717 Key West Avenue, Suite 100 Rockville, Maryland 20850 United States | |
| Phone | 301-869-9683 |
| Website | opgen.com |
Stock Details
| Ticker Symbol | OPGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001293818 |
| CUSIP Number | 68373L307 |
| ISIN Number | US68373L4068 |
| Employer ID | 06-1614015 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oliver Schacht Ph.D. | Executive Vice President of Corporate Development |
| David Elliot Lazar | Chief Executive Officer and Chairman |
| Vadim Sapiro | Chief Information Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 8-K | Current Report |
| Apr 17, 2024 | 8-K | Current Report |
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 3, 2024 | SC 14F1 | Filing |
| Apr 1, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 29, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 8, 2024 | 8-K | Current Report |